FilingReader Intelligence

Alembic Pharmaceuticals gains US approval for carbamazepine tablets

July 26, 2025 at 06:19 AM UTCBy FilingReader AI

Alembic Pharmaceuticals announced US FDA final approval for its Carbamazepine Extended-Release Tablets in 100mg, 200mg, and 400mg strengths, the generic equivalent of Novartis's Tegretol-XR.

The market size for these tablets is estimated at $71m for the twelve months ending March 2025. This brings Alembic's total US FDA approvals to 225.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when ALEMBIC PHARMACEUTICALS publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →